Цитата:
In very difficult-to-cure patients (patients with NS5A
RASs who failed twice to achieve SVR after a combination
regimen including a protease and/or an NS5A inhibitor),
the triple combination of sofosbuvir, velpatasvir
and voxilaprevir, or the triple combination of sofosbuvir,
glecaprevir and pibrentasvir can be administered for 12
weeks with weight-based ribavirin (1,000 or 1,200 mg in
patients <75 kg or ≥75 kg, respectively) and/or treatment
duration can be prolonged to 16 to 24 weeks, based on
an individual decision in the context of a multidisciplinary
team including experienced treaters and virologists
|
EASL Recommendations on Treatment of Hepatitis C 2018
Таким образом, для начала следует провести исследование на наличие резистентных мутаций вируса.
Перелечивание возможно комбинацией Глекапревир+Пибрентавир+Рибавирин 12 недель, но длительность терапии может быть и больше (16-24 недели).